Zymeworks BC Inc
NASDAQ:ZYME 4:00:00 PM EDT
| Market Cap (Intraday) | 1.19B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $15.42 |
| 50-Day MA | $14.00 |
| 200-Day MA | $13.20 |
Zymeworks BC Inc Stock, NASDAQ:ZYME
108 Patriot Drive, Suite A, Middletown, Delaware 19709
Canada
Phone: +1.302.274.8744
Number of Employees: 286
Description
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.